Kamada Ltd. is enhancing efforts to understand and utilize CYTOGAM®, its cytomegalovirus immune globulin, for organ transplant patients facing severe CMV risks. CMV infections affect 20% to 60% of transplant recipients, with no foolproof prevention method or vaccine available, making it a critical post-transplant concern. CYTOGAM is designed to prevent CMV disease in kidney, lung, liver, pancreas, and heart transplant patients by complementing standard antiviral treatments, offering a dual approach to combat the virus.
The company has launched a comprehensive post-marketing research program to generate new data supporting CYTOGAM's benefits, explore its mechanism of action, and investigate potential new applications. This initiative is backed by collaborations with Key Opinion Leaders and presentations of clinical data at medical conferences, which have shown CYTOGAM's effectiveness in improving outcomes for high-risk transplant recipients. Studies indicate it provides superior anti-CMV antibody levels compared to regular immune globulin intravenous treatments, as detailed in research available at https://www.kamada.com/cytofam-research.
CMV is a significant factor in graft rejection and mortality among transplant patients, highlighting the importance of Kamada's commitment to advancing CMV disease management. The new research program addresses unmet needs in organ transplantation, potentially improving quality of life for these individuals. By focusing on CYTOGAM, Kamada aims to provide a pivotal solution in the fight against CMV, with ongoing studies exploring its broader implications in transplant care, supported by data from https://www.transplantjournal.org/cmv-prevention.
